9.64
-0.12 (-1.18%)
| Previous Close | 9.75 |
| Open | 9.80 |
| Volume | 78,305 |
| Avg. Volume (3M) | 88,847 |
| Market Cap | 209,829,760 |
| Price / Earnings (Forward) | 26.88 |
| Price / Sales | 13.17 |
| Price / Book | 4.01 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Operating Margin (TTM) | -125.87% |
| Diluted EPS (TTM) | -1.28 |
| Total Debt/Equity (MRQ) | 2.20% |
| Current Ratio (MRQ) | 17.14 |
| Operating Cash Flow (TTM) | -7.33 M |
| Levered Free Cash Flow (TTM) | -4.74 M |
| Return on Assets (TTM) | -26.73% |
| Return on Equity (TTM) | -56.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Alpha Cognition Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.04% |
| % Held by Institutions | 44.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Act Capital Management, Llc | 30 Jun 2026 | 51,500 |
| Berkshire Asset Management Llc/Pa | 30 Jun 2026 | 19,824 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WILLS ROBERT JAMES | 9.75 | - | 10,000 | 97,500 |
| Aggregate Net Quantity | 10,000 | |||
| Aggregate Net Value ($) | 97,500 | |||
| Aggregate Avg. Buy ($) | 9.75 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WILLS ROBERT JAMES | Director | 21 Aug 2026 | Buy (+) | 10,000 | 9.75 | 97,500 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |